Innovative Molecular Diagnostics NuProbe specializes in high-sensitivity genomics panels for challenging DNA biomarkers such as CNVs, gene fusions, and low-frequency mutations, positioning it as a key provider for laboratories seeking advanced diagnostic solutions in oncology and genetic testing.

Strategic Industry Partnerships Recent collaborations with Bio-Rad Laboratories and Signum Health highlight NuProbe’s ability to integrate its technologies into multiplexed digital PCR assays, opening opportunities to sell into established diagnostic and research platforms.

Strong Funding Backing With $53 million in funding and significant investments from China-based investors and healthcare funds, NuProbe demonstrates robust financial health and growth potential, making it an attractive partner for expanding sales efforts in genomics.

Innovative Publication Track Record Publication of its QASeq methodology in Nature Communications showcases NuProbe’s thought leadership and technological advancement, appealing to research institutions and biotech firms seeking cutting-edge solutions.

Global Presence and Growth Operates across Houston and Shanghai with a focus on molecular diagnostics and genomics, providing multiple entry points for global sales expansion and cross-border collaborations in the rapidly evolving biotech market.